2016
DOI: 10.1188/16.onf.43-05ap
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence, Duration, Severity, and Distress of Chemotherapy-Related Gastrointestinal Symptoms in Patients With a Hematologic Malignancy

Abstract: Future research should include measures of clinically relevant GI symptoms that may be emerging with new cancer therapies and toxicity prevention protocols.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 9 publications
(6 citation statements)
references
References 25 publications
0
6
0
Order By: Relevance
“…A more detailed report of participant inclusion criteria is reported elsewhere. 8 Patients with a hematologic malignancy were selected because these patients are rarely included in cancer symptom studies or are lumped together with solid tumor diagnoses.…”
Section: Design and Samplementioning
confidence: 99%
See 1 more Smart Citation
“…A more detailed report of participant inclusion criteria is reported elsewhere. 8 Patients with a hematologic malignancy were selected because these patients are rarely included in cancer symptom studies or are lumped together with solid tumor diagnoses.…”
Section: Design and Samplementioning
confidence: 99%
“…Based on this definition, symptom data from the modified 41-item MSAS were reduced to 30 items by removing symptoms that did not meet the criteria to be considered clinically relevant (Table 1). 8 Symptom data from the 30 clinically relevant items were included for analysis.…”
Section: Instrumentsmentioning
confidence: 99%
“…23 We modified the original 32-item MSAS to include 9 additional gastrointestinal symptoms identified by cancer symptom experts as being relevant to people with cancer. 24 Symptom interference with daily life was assessed using the symptom interference Subscale of the M. D. Anderson Symptom Inventory (MDASI). 25 Participants were asked to rate how much their symptoms interfered with aspects of their life in the past week.…”
Section: Methodsmentioning
confidence: 99%
“…For each symptom present, severity is rated on a 1- to 4-point scale, from “slight” to “very severe.” The original MSAS has well-documented reliability and validity among the oncology population ( α = .83 to .88) 23 . We modified the original 32-item MSAS to include 9 additional gastrointestinal symptoms identified by cancer symptom experts as being relevant to people with cancer 24 …”
Section: Methodsmentioning
confidence: 99%
“…Symptoms were assessed using a modi ed version of the Memorial Symptom Assessment Scale (MSAS) [29,30]. Participants were provided a list of 41 symptoms and were asked to indicate whether any of the symptoms were present in the past week.…”
Section: Data Collection Proceduresmentioning
confidence: 99%